If Bristol Buys ImClone, Who Will Buy Bristol?

If Bristol-Myers Squibb winds up buying ImClone, Bristol itself could become a more appealing acquisition target. Bristol — a perennial buyout candidate — has been busy turning itself into a biotech-pharma hybrid. The company already owns about 17% of ImClone, and the two companies co-market ImClone’s cancer drug Erbitux. Buying ImClone would give Bristol full [...]